Mural OncologyNASDAQ: MURA

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences.

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee.

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30.

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.